NCT02149706View on ClinicalTrials.gov

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

PHASE2UnknownINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 9, 2020

Primary Completion Date

March 9, 2022

Study Completion Date

March 9, 2022

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

NeuroVax

NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA

BIOLOGICAL

IFA Incomplete Freund's Adjuvant

IFA Placebo Incomplete Freund's Adjuvant

Trial Locations (1)

92129

CRO, San Diego

Sponsors
All Listed Sponsors
lead

Immune Response BioPharma, Inc.

INDUSTRY

collaborator

cro

AMBIG